-
Longevity has always been committed to creating high-quality products and services for people through cutting-edge technology. To make human beings live a longer and healthier life.
-
Longevity extends the length of life, expands the width of life, enriches the depth of life, and explores the true meaning of life in multiple dimensions, with the unique perspective.
-
Longevity has always devoted itself to taking the future health of the public as its own duty, adhering to “customer first”, wholeheartedly guarding the quality of life, maintaining the dignity of life and showing the beauty of life.
-
Longevity aspires to become a benchmarking enterprise in the health care industry, create value for shareholders and employees, provide high-quality products and services for ordinary consumers, and contribute to social development.
-
Company Overview
Company Profile
Longevity pays close attention to the future health of the public and follows a sustainable development path.
Professional integrity
Integrity and honesty are the first. Adhere to fairness, justice and openness.
The layout of our industry chain spread over the world with Japan, China, Europe and America as the core.
Cole Value
Customer First，Open cooperation，Forging ahead with determination，Embracing changes.
Phase I: Foundation and Development (2013-2015)
Since the outbreak of SARS, the founding team of Longevity Group initiated the medical device industry such as epidemic prevention materials and medical equipment. Later, our Group expanded into four emerging business sectors such as bio-pharmaceuticals, elderly care service, early screening for cancer, and Healthcare Cloud, gradually developing the competitive advantage with research and development as its core competitiveness.
In 2013,
the founding team of Longevity Group engaged in cross-border medical business and introduced Japanese high-end medical services into the Chinese market.
Phase II: Independent Research and Development and Brand Creation (2015-2017)
With the theme of independent innovation, the Group increased its investment in technology research and improved its capacity of independent innovation in technology. “Longkare products” and “Anti-viral Masks” were widely popular among consumers in the United States, Europe, Japan and other countries and were sold in hospitals, shopping malls, and pharmacies. The brand building of the Group has laid a solid foundation for the sales of our products.
Phase III: Initiation of the Early Screening for Cancer Program (2017-2018)
Based on the Japan’s advanced cancer screening technology and resource advantages, the Group created a new model of precision medicine, telemedicine and international green referrals in cooperation with top biomedical research institutions in China.
Phase IV: Technological Innovation and Capital Operation (2018-2019)
Healthcare Cloud marked the Group’s entrance into a new phase of development. By means of capital expansion, the Group took more efforts to promote the technical innovation of existing products and the development of new products.
Phase V: Technological Innovation and Capital Operation ( From 2019 to now)
By means of capital expansion, the Group has taken more efforts to promote the technical innovation of existing products and the development of new products. With the expansion and development of business, the Group has not only expanded through its own accumulation of matters, but also accelerated its growth through mergers and acquisitions. Taking the listing as an opportunity, we will achieve a sustainable, rapid and stable development as well as higher corporate value.
Going forward, we will continue to make contributions to health career of mankind...
In 2015
Longevity founding team to expand cross-border medical and telemedicine business.
In 2018
Longevity Group set up New Wall Holdings in Hong Kong to develop the healthcare industry with a “two-wheel drive” strategy combining industry and finance.
In 2020,
we raised 2 million medical masks from overseas and donated them to local governments and hospitals so as support China's fight against the Covid-19 pandemic.
In 2021
we completed the layout of four major industrial chains and the registration of related factories, and obtained the qualifications of the medical device.
Company history
